Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANTARES PHARMA, INC.

(ATRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Antares Pharma, Inc. Reaffirms Revenue Guidance for the Full Year 2021

08/05/2021 | 08:08am EDT

Antares Pharma, Inc. reaffirmed revenue guidance for the full year 2021. For the year, the company expects revenue to be in the range of $175-200 million, which represents a 17% to 34% year-over-year growth rate and assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic.


ę S&P Capital IQ 2021
All news about ANTARES PHARMA, INC.
09/30ANTARES PHARMA : Starts Phase 1 Study of ATRS-1902 Drug for Acute Adrenal Insufficiency Tr..
MT
09/30ANTARES PHARMA : Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
AQ
09/30Antares Pharma, Inc. Initiates Phase I Study for ATRS-1902 for Adrenal Crisis Rescue
CI
09/08ANTARES PHARMA : to Participate in the H.C. Wainright 23rd Annual Global Investment Confer..
PU
09/08Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conf..
GL
08/18ANTARES PHARMA, INC. : Regulation FD Disclosure (form 8-K)
AQ
08/06Antares pharma reports second quarter 2021 financial and operating resultsewing
AQ
08/05ANTARES PHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS O..
AQ
08/05ANTARES PHARMA, INC. : Results of Operations and Financial Condition, Financial Statements..
AQ
08/05Antares Pharma, Inc. Reaffirms Revenue Guidance for the Full Year 2021
CI
More news
Analyst Recommendations on ANTARES PHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 187 M - -
Net income 2021 17,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 34,0x
Yield 2021 -
Capitalization 585 M 585 M -
Capi. / Sales 2021 3,12x
Capi. / Sales 2022 2,52x
Nbr of Employees 185
Free-Float 97,9%
Chart ANTARES PHARMA, INC.
Duration : Period :
Antares Pharma, Inc. Technical Analysis Chart | ATRS | US0366421065 | MarketScreener
Technical analysis trends ANTARES PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,45 $
Average target price 6,64 $
Spread / Average Target 92,5%
EPS Revisions
Managers and Directors
Robert F. Apple President, Chief Executive Officer & Director
Fred M. Powell Chief Financial Officer & Executive Vice President
Leonard S. Jacob Chairman
Jonathan S. Jaffe Vice President-Clinical & Medical Affairs
Peter C. Richardson Chief Medical Officer & Executive VP-Research
Sector and Competitors
1st jan.Capi. (M$)
ANTARES PHARMA, INC.-13.53%585
ABBOTT LABORATORIES7.31%208 430
MEDTRONIC PLC9.06%167 957
BECTON, DICKINSON AND COMPANY-3.62%69 695
HOYA CORPORATION20.71%54 180
DEXCOM, INC.47.27%53 648